In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilising BRAF MEK inhibitors in patients after an initial period of tumour shrinkage.

During the new two-year study, Lo and his team took 43 tumour samples from 15 patients before they were prescribed the new BRAF MEK inhibitor combo drugs and then after they relapsed due to the melanoma developing drug resistance.

The participants had all benefited from the combo therapy initially, but after periods of time the tumours regressed.

All the tumours biopsied from the patients were subjected to in-depth analysis of the genetic material extracted from the tumours.

This analysis of patient-derived tumours then provided leads for the investigators to study how melanoma cells grown in Lo's laboratory rewired their growth circuitry to get around the combo inhibitors.

Lo's team found that the melanoma cells resist the combo therapy of BRAF MEK inhibitors by developing highly unusual genetic changes in certain key cancer genes.

These signature genetic changes or configurations not only mark the presence of drug resistance melanoma cells but also tell us about potential new ways to shut them off.

"We need to find ways to go beyond the BRAF MEK drug combination, by possibly finding a third drug, or alter how we prescribe the combo of drugs," said Lo, UCLA associate professor of dermatology.

"The idea is to eventually suppress melanoma drug resistance even before it arises."

"In most cases, melanoma eventually becomes resistant," said Dr Antoni Ribas, JCCC member and professor of haematology and oncology, and a co-author of the study.

"We now understand the molecular basis of the resistance mechanisms, which leads to the planning of new treatment approaches to disable these mechanisms."

An estimated 70,000 new cases of melanoma are diagnosed each year in the United States.

Of those, 8,000 people will die of the disease.

About 50 percent of patients with metastatic melanoma, or 4,000 people a year, have a mutated protein called a BRAF mutation.

Lo and Ribas previously collaborated on several seminal drug resistance studies investigating how melanoma resisted the then-experimental drug PLX4032, which is now known as vemurafenib (Zelboraf) and was approved by the FDA in 2011.

These studies have provided critical insights that led to development of the current combo therapy for melanoma using BRAF MEK inhibitors and additional on-going clinical trials.

Lo hopes this new study will also lead to more effective therapies for patients.

"If we understand how a disease fights your therapy, then we can start to design more effective treatment strategies," Lo said.

Source: Jonsson Comprehensive Cancer Center